Dioseve Raises Over ¥1 Billion in Series A Extension Round, Attracting Overseas Investors and Major Pharmaceutical Companies, and Selected for NEDO DTSU
AI Summary (NQ-processed)
Dioseve Inc. has successfully closed its Series A extension round, raising over ¥1 billion, bringing its total funding to ¥2.5 billion. The round saw participation from overseas investors and major pharmaceutical companies, accelerating the commercialization of its iPS cell-derived oocyte in vitro maturation product, 'ReproNest'. The company was also selected for the NEDO DTSU program.
AI Analysis
Frequently Asked Questions
Q: What problem does Dioseve's 'ReproNest' aim to solve?
A: It aims to reduce patient burdens such as physical and mental stress from hormone stimulation, frequent clinic visits, self-injections, and medication costs in conventional IVF.
Q: How is iPS cell technology applied to reproductive medicine?
A: Dioseve utilizes iPS cell differentiation induction technology to develop products that support in vitro maturation of immature oocytes, contributing to improved efficiency and reduced patient burden in reproductive medicine.
Q: How will this funding impact Dioseve's business?
A: The funds raised will accelerate the verification for commercialization of the product 'ReproNest,' the establishment of manufacturing and quality control systems, and domestic and international business development.